VY1706
Gene Therapy Target: tau mRNA, tau
Voyager Therapeutics, Inc.
Most recent annual filing: 2026-03-09
Pipeline (7 active programs)
VY7523
frataxin gene therapy
NBIB-'223 Gene Therapy Target: FXN
glucosylceramidase beta 1 gene therapy
Gene Therapy Target: GBA1
TDP-43 targeting small molecule
Small Molecule Target: TDP-43
Technology platforms
TRACER
Tropism Redirection of AAV by Cell-type-specific Expression of RNA — RNA-based AAV capsid discovery platform enabling rapid discovery of capsids with robust BBB penetration and enhanced CNS tropism in multiple species including NHPs; used to generate novel capsids for intravenously delivered AAV gene therapies targeting neurological diseases including Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, SMA, and Huntington's disease.
Targets: ALPL, ApoE4, ApoE2
Voyager NeuroShuttle
Non-viral delivery platform leveraging novel receptor-binding molecules (initially ALPL receptor) to transport multiple modalities of neurotherapeutics across the blood-brain barrier; focus on neurological diseases. Proof-of-concept data in murine studies demonstrated sustained brain expression over three weeks.
Targets: ALPL
Biotech Distilled coverage (5)
- 2026-05-16 UPDATE: Voyager Therapeutics (VYGR) - EcoR1 Walks 🔒 Paid
- 2026-05-14 UPDATE: Voyager Therapeutics (VYGR) - The AAV Liver Ghost Got Quieter 🔒 Paid
- 2026-05-08 UPDATE: Voyager Therapeutics (VYGR) - The Q1 Print Answers Two Open Questions 🔒 Paid
- 2026-04-27 UPDATE: Voyager Therapeutics (VYGR) - The Second C-Suite Exit and the 240M-Share Tell 🔒 Paid
- 2026-03-17 Voyager Therapeutics (VYGR) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.